Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE III CLINICAL TRIAL OF PRUSOGLIPTIN TABLETS IN COMBINATION WITH DAPAGLIFLOZIN TABLETS AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS ACHIEVES POSITIVE TOPLINE RESULTS

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Prusogliptin Tablets (the "**Product**") developed by the Group has recently obtained topline analysis data in a Phase III clinical trial of the triple combination therapy of prusogliptin, dapagliflozin and metformin in patients with type 2 diabetes mellitus ("**T2DM**").

Prusogliptin is a dipeptidyl peptidase-IV ("**DPP-4**") inhibitor. By inhibiting DPP-4, it elevates the level of endogenous active glucagon-like peptide-1 ("**GLP-1**"), increases insulin secretion in a glucose concentration-dependent manner, and inhibits glucagon secretion, thereby improving hyperglycaemia. Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor (SGLT2i), which can inhibit the reabsorption of glucose by the kidneys and promote urinary glucose excretion, thereby lowering blood glucose. Metformin increases the uptake and utilisation of glucose by peripheral tissues, reduces hepatic glucose production, inhibits the intestinal absorption of glucose, and improves insulin sensitivity. The combination therapy of prusogliptin, dapagliflozin and metformin covers multiple pathophysiological defects of T2DM through complementary mechanisms, enhancing the glucose-lowering efficacy while maintaining a low risk of hypoglycaemia, and possesses multiple clinical advantages such as lowering blood pressure and body weight, protecting pancreatic β-cells, and providing cardiorenal benefits.

This trial is a multicentre, randomised, double-blind, parallel-controlled Phase III clinical trial, aiming to evaluate the efficacy, safety and pharmacokinetic (PK) profile of the triple combination therapy of prusogliptin, dapagliflozin and metformin in the treatment of T2DM. The primary endpoint is the change from baseline in glycated haemoglobin ("**HbA1c**") at week 24 of treatment.

This pivotal study has met its pre-specified primary endpoint and achieved positive topline results. Statistical analysis showed that after 24 weeks of treatment with the triple combination of prusogliptin, dapagliflozin and metformin, the reduction in HbA1c from baseline in patients was significantly superior to that of the treatment groups receiving dapagliflozin in combination with metformin or prusogliptin in combination with metformin. Furthermore, the triple combination therapy regimen demonstrated a favourable safety profile, with an overall incidence of adverse events comparable to that of the aforementioned dual combination therapies, and did not increase safety risks.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.